CEO Executive AssistantMedical affairs has evolved from a supporting function into a strategic core of pharmaceutical and biotech companies. For organizations with products in late-stage development or recently approved, the medical affairs team is responsible for building scientific credibility with the medical community, engaging key opinion leaders in genuine scientific exchange, supporting evidence generation, and ensuring that healthcare professionals have accurate, balanced information about the company’s medicines. The CEO who does not understand and actively support the medical affairs function is leaving one of the company’s most important commercial and scientific assets underutilized.
CEO engagement with medical affairs operates at a specific level: setting the strategic direction for scientific engagement, participating in medical advisory board sessions that benefit from executive sponsorship, meeting with the most senior key opinion leaders where a CEO-level relationship matters, and reviewing medical affairs performance data as part of broader portfolio oversight. None of this happens well without administrative infrastructure that schedules, prepares, and follows up on the CEO’s medical affairs commitments.
This article examines how skilled executive assistants provide pharma CEO medical affairs admin support across four areas: medical affairs leadership meetings, key opinion leader engagement scheduling, medical advisory board coordination, and scientific exchange reporting.
The CEO’s Stake in Medical Affairs Oversight
Medical affairs bridges the scientific community and the commercial organization. When it operates well, the company builds credibility with physicians, payers, and health systems that translates into appropriate prescribing decisions, formulary access, and long-term brand trust. When it operates poorly, or when it is perceived as commercially driven rather than scientifically rigorous, the company loses the trust that medical affairs is designed to build.
The CEO’s oversight role is not to manage medical affairs operations. That belongs to the Chief Medical Officer, VP of Medical Affairs, or equivalent leader. The CEO’s role is to ensure the function has the resources and strategic clarity to perform at the level the company needs, to represent the company’s scientific commitments credibly to external stakeholders, and to participate in select high-value engagements that benefit from CEO presence. All of this requires consistent scheduling, thorough preparation, and disciplined follow-up.
Medical Affairs Leadership Meeting Coordination
Regular structured meetings between the CEO and medical affairs leadership are the primary mechanism through which the CEO maintains current intelligence on the function’s performance and priorities. These meetings cover scientific platform strategy, engagement program progress, pipeline-related medical affairs activities, and any emerging issues that require executive attention.
Establishing a Sustainable Meeting Cadence
The executive assistant establishes a meeting cadence for the CEO’s engagement with medical affairs leadership, typically including a monthly or bimonthly briefing with the Chief Medical Officer or VP of Medical Affairs, periodic deeper-dive sessions on specific therapeutic areas or products, and ad-hoc meetings when strategic decisions or issues require CEO input.
Protecting this cadence is as important as establishing it. Medical affairs leadership meetings are frequently displaced by commercial priorities, investor events, and operational emergencies. The EA monitors schedule pressure and works proactively to reschedule meetings that get bumped rather than allowing them to simply fall off the calendar. Consistent CEO engagement with medical affairs leadership signals organizational priority; inconsistent engagement signals the opposite.
Pre-Meeting Briefing Coordination
Before each medical affairs leadership meeting, the EA coordinates preparation of a briefing package that gives the CEO substantive context: key performance indicators for the medical affairs program, recent scientific publication activity, upcoming congress engagements, KOL relationship status by therapeutic area, advisory board outcomes, and any issues requiring CEO decision.
The EA works with the medical affairs team’s administrative support or chief of staff to gather these materials, ensures they are assembled in a format appropriate for executive review, and delivers them to the CEO with sufficient lead time. For CEOs who have limited daily review time, the EA calibrates briefing length to what can realistically be absorbed before the meeting.
Action Tracking and Meeting Follow-Through
After medical affairs leadership meetings, the EA documents any commitments the CEO made, assigns follow-up actions to appropriate staff, and ensures those actions are tracked to completion. When the CEO agreed to review a specific MSL engagement strategy, approve resource requests for a new therapeutic area, or participate in a particular congress symposium, those commitments are logged and surfaced before they create downstream delays.
Key Opinion Leader Engagement Scheduling
Key opinion leaders are the physicians, researchers, and thought leaders whose views carry disproportionate influence on how a medical community perceives a therapeutic area and the medicines within it. Building genuine relationships with these individuals takes years and requires consistent, respectful engagement at multiple levels of the organization. The CEO’s direct engagement with the most senior KOLs in a company’s core therapeutic areas is a relationship investment that medical affairs and commercial teams cannot substitute.
Identifying and Scheduling CEO-Level KOL Engagements
Not every KOL relationship requires CEO engagement. Most are managed effectively by medical science liaisons, medical directors, and medical affairs leaders. The CEO’s time is reserved for a small number of relationships where executive presence adds specific value: KOLs who are advising on enterprise strategy, international thought leaders being cultivated for global advisory roles, or academic leaders with whom the company wants to explore research collaboration at the investigator-initiated study level.
The EA works with the Chief Medical Officer and the medical affairs leadership team to identify which KOL engagements genuinely require CEO participation, then manages the scheduling process for those meetings. This often involves coordinating with academic medical center scheduling systems, managing international time zone logistics, and accommodating the busy schedules of physicians who have limited availability outside of conference settings.
Pre-Engagement Briefing Preparation
Before any CEO meeting with a KOL, the EA coordinates preparation of a thorough briefing. This includes the KOL’s professional background and current institutional affiliation, their publication history and areas of scientific focus, their relationship history with the company, any past advisory interactions, their views on the therapeutic area as expressed in recent publications or presentations, and talking points from the medical affairs team on the topics the company wants to explore.
This briefing allows the CEO to engage in genuine scientific conversation rather than a superficial relationship call. KOLs who feel that the CEO has actually engaged with their work and understands the therapeutic landscape come away from these meetings with a different impression than those who feel they have met with a business executive who read a one-page summary.
Post-Engagement Follow-Up
After CEO-level KOL meetings, the EA captures debrief notes from the CEO and coordinates follow-up actions with the medical affairs team. If the KOL expressed interest in a clinical collaboration, raised questions about a specific data package, or offered to participate in an advisory board, those commitments require organized follow-through. The EA ensures the medical affairs team has what they need to move those next steps forward promptly.
For related context on how executive assistants support pharmaceutical CEO engagement with regulatory milestones that shape the scientific environment, regulatory affairs coordination covers FDA meeting scheduling and submission tracking workflows that intersect with the medical affairs program.
Medical Advisory Board Coordination
Medical advisory boards bring together senior physicians and researchers to provide scientific guidance to pharmaceutical companies on therapeutic area strategy, clinical development questions, and evidence generation priorities. CEO participation in advisory board meetings is typically limited to select sessions: an opening welcome, strategic presentations where the CEO outlines the company’s direction, or discussions of enterprise-level decisions that benefit from advisory board input.
Managing the CEO’s Advisory Board Calendar
The EA maintains the CEO’s medical advisory board calendar, tracking which boards the company sponsors, the schedule of upcoming board meetings, and which sessions have been identified as appropriate for CEO participation. Advisory board meetings are typically scheduled far in advance, which creates an opportunity for the EA to block CEO time early and protect those commitments against displacement.
For advisory boards that meet annually, the EA builds the scheduling process into the annual calendar planning cycle, ensuring that the CEO’s participation is accounted for in the overall executive calendar before competing priorities fill the available time.
Coordinating Materials and Logistics
Medical advisory board sessions attended by the CEO require specific preparation: an understanding of the advisory board’s membership and expertise, the agenda for the CEO’s participation, briefing materials on strategic questions the board is being asked to address, and any logistical details the CEO needs including meeting location, format, attendee list, and protocol for interacting with board members.
The EA works with the medical affairs team and any external meeting management partner to coordinate these materials, confirms logistics in advance, and ensures the CEO’s participation goes smoothly from arrival through departure.
Capturing Advisory Board Outcomes
After meetings where the CEO participated, the EA coordinates with the medical affairs team to capture advisory board outcomes and recommendations that are relevant to CEO-level decision-making. When an advisory board provides strategic input on a pipeline asset, expresses concerns about a development approach, or recommends a shift in evidence generation strategy, that input should reach the CEO in a summarized, actionable form. The EA ensures this feedback loop closes rather than leaving advisory board outputs sitting in meeting notes that never reach executive attention.
Scientific Exchange Reporting
The CEO of a pharmaceutical company needs periodic visibility into the scientific exchange program as a whole: how the medical affairs function is performing against engagement objectives, what the medical community’s reception of the company’s scientific data looks like, and how the company’s scientific presence at key congresses is building brand credibility with healthcare professionals.
Quarterly Medical Affairs Performance Reviews
The EA coordinates a quarterly review cycle in which the CEO receives a structured update on medical affairs program performance. This review typically covers MSL interaction metrics, publication activity, congress symposia outcomes, advisory board feedback themes, pipeline-related medical education activity, and any compliance matters relevant to the CEO’s oversight role.
For this review to be substantive, the EA works with the medical affairs leadership team to define the reporting framework, establish what data is collected and how, and ensure the reporting cadence is maintained consistently. The CEO who receives a comprehensive medical affairs briefing each quarter has visibility into one of the company’s most strategically important functions without needing to be involved in day-to-day operations.
Supporting Board and Investor Scientific Communications
Pharmaceutical CEOs are frequently called upon to communicate the company’s scientific strategy and evidence base to the board of directors, to investors at scientific-focused investor conferences, and to the broader healthcare community. The EA supports the preparation of these communications by coordinating with the medical affairs and communications teams, ensuring scientific accuracy in external-facing materials, and managing the CEO’s schedule for scientific communication commitments throughout the year.
For major medical congresses where the company has a significant scientific presence, the EA coordinates the CEO’s congress schedule: which symposia the CEO will attend, which investigator or advisory meetings require CEO presence, media or analyst interactions on the sidelines of the congress, and the overall logistics of the CEO’s attendance.
Maintaining a Scientific Engagement Log
The EA maintains a log of the CEO’s scientific engagements: KOL meetings, advisory board participations, congress appearances, and significant scientific communications. This log serves as institutional memory, supporting continuity in KOL relationships and providing the data needed for annual reviews of the medical affairs engagement strategy.
For additional context on how executive assistants support pharmaceutical CEO development oversight earlier in the pipeline, clinical trial coordination covers the scheduling and milestone tracking workflows that keep the CEO informed on trial progress and pipeline decisions.
The Administrative Foundation of Scientific Leadership
Pharmaceutical CEOs who are recognized as genuine scientific leaders, not just business executives who happen to lead drug companies, have typically invested in the external engagements that build that credibility: authentic conversations with leading physicians, genuine participation in advisory processes, and transparent communication of the company’s scientific evidence. This investment requires time and preparation. It requires meeting KOLs with current knowledge of their work. It requires advisory board participation that adds real value to the advisory conversation.
The executive assistant makes this investment sustainable. By owning the scheduling, briefing, and follow-up infrastructure around the CEO’s scientific engagements, the EA allows the CEO to show up fully in every interaction rather than squeezing an underprepared KOL meeting into a calendar gap between other commitments.
The result is a CEO who is known in the medical community not just by title but by the quality of their scientific engagement. That reputation is among the most durable competitive advantages a pharmaceutical company can build, and it is built one well-prepared meeting at a time.